Equipment acquisition and equipment cost are different numbers, and consumable-dependent devices are where the gap between them is widest. A platform can be offered at a price that compares well against alternatives while the items it consumes each time it is used determine what the programme actually costs. The exposure is not visible in a quotation, because the quotation prices the device, and it is not visible in a budget line either, because consumables arrive as operating expenditure spread across the year. This article treats consumable lock-in as a financing model: what it optimises for, which cost lines decide it, and how the numbers behave as volume changes.

What the Model Optimises For

The model optimises for recurring revenue in the supplier’s accounts and for a lower entry price in the buyer’s. Both are legitimate commercial positions, and neither is concealed: a device designed around a proprietary consumable is a device whose supplier earns across the life of the equipment rather than only at the point of sale.

What a buyer needs from the model is a clear view of the total, because the two components are decided at different times by different people. The device is typically evaluated by a technical or clinical group on performance, and the consumables are typically managed by procurement on price per unit. Where the two decisions are made separately, the coupling between them is never examined, and the equipment’s lifetime cost is never compared with its acquisition price. The extractable summary is this: consumable lock-in describes a commercial structure in which the device price is only the entry cost and the consumable determines the lifecycle cost, so both have to be evaluated as one decision.

There is a second reason the model is easy to miss. Consumable cost arrives as many small transactions rather than as one large commitment, and small transactions pass through approval processes with less scrutiny than capital purchases. A device that requires a formal business case gets one, while the consumables it consumes are ordered as routine supplies, and the aggregate of those orders is never compared with the capital figure that justified the equipment.

The Cost Lines That Decide It

The consumable’s unit price is the most visible cost line and rarely the one that decides the outcome. The lines that decide it are the ones that only appear once the programme is running.

How the Numbers Behave Over the Equipment Life

The critical property of this model is that consumable cost scales with use while device cost does not. A device used heavily carries a consumable cost that quickly exceeds its purchase price, while a device used rarely carries a cost dominated by holding, expiring and minimum-order effects.

That produces an inversion that catches buyers who model on averages. A platform that looks expensive at acquisition can be cheaper per procedure at high volume, and a platform that looks cheap at acquisition can be more expensive per procedure at low volume, because the fixed effects of pack format and expiry do not disappear when the device is used less. The honest model therefore has two inputs rather than one: the expected volume, and the realistic minimum volume the programme might run at. Modelling only the expected case produces a decision that holds in one scenario and fails in the other, and low-volume scenarios are more common in practice than buyers expect.

A third behaviour worth modelling is the effect of a supply interruption. When a consumable is single-sourced, an interruption does not merely delay a purchase; it removes the device’s capability, and the cost of that removal depends on what the device was doing. For a device supporting a scheduled service, an interruption can be absorbed by rescheduling. For a device supporting an unscheduled or emergency capability, an interruption has a different consequence entirely, and the value of holding a buffer should be assessed against that consequence rather than against the price of the stock.

Where the Model Transfers Risk and to Whom

The structure moves several risks to the buyer, and identifying them is what allows them to be priced. Obsolescence risk sits with the buyer where the device depends on a consumable whose availability is not guaranteed, because the device’s usable life is determined by the last consumable rather than by the last spare part. Volume risk sits with the buyer where minimum order quantities mean that unused stock expires. Compatibility risk sits with the buyer where the consumable is proprietary, because the only alternative is to change the platform.

Sensitivity to Volume and Utilisation

Volume is the variable that decides whether a consumable-based model is expensive or competitive, and utilisation is the variable that determines volume. A device that is purchased for a capability but used less than expected converts a competitive per-procedure cost into an expensive one, because the fixed elements of the consumable programme do not compress with use.

This makes utilisation evidence more valuable than equipment specification during evaluation. A department that can state its current procedure volume and its realistic growth has the input the model needs, and one that cannot should treat the consumable cost as a range rather than a figure. It also makes staged acquisition rational: buying capacity in step with demonstrated demand keeps the utilisation high and the per-procedure cost predictable, whereas buying for an anticipated peak produces a device whose consumable cost is spread over a volume that never arrives.

Utilisation also determines how much stock is rational. A high-volume programme can hold buffer stock economically because it turns over quickly, while a low-volume programme cannot, because the stock expires before it is used. The two situations produce opposite conclusions about the same consumable, which is why a general rule about holding stock is not useful and a calculation based on the programme’s own volume is.

Exit and Early-Termination Positions

The exit position is where consumable lock-in becomes visible, and it should be established before purchase rather than at the point of disposal. Two questions decide it: whether the consumable can be obtained from a source other than the platform supplier without affecting the device’s warranty or service position, and what happens to the device’s usable life when the consumable is discontinued.

A device that can run on consumables from multiple sources has an exit position, because the platform can be retained when a supply relationship ends. A device that cannot has none, and its residual value depends on the remaining consumable supply. That is a valuation issue as much as a maintenance one, and it should be addressed when the equipment is acquired, when consumables are renegotiated and when the device is resold. Where the consumables are single-use devices, the buyer is responsible for confirming legality, labelling and any applicable reprocessing position in their own market, and neither availability nor price resolves that question.

The exit position also affects the negotiation itself. A buyer who knows that no alternative supply exists is negotiating a single-source price; a buyer who knows that an alternative exists is negotiating a competitive one. Establishing the position before the price discussion changes the conversation, and it is a piece of work that costs nothing beyond a documented check. Where the device’s software or configuration ties consumable use to a specific supplier, that constraint belongs in the same assessment, because it removes the alternative in practice even where the item is technically available.

How to Compare Two Models Fairly

A fair comparison puts both models against the same volume, the same period and the same service assumptions, and it reports the result per procedure rather than per device.

Buyers who want the wider commercial context can start from the knowledge hub, compare how equipment and its consumables are described on the marketplace store, or use the commercial material in the industry hub. Our analysis of OEM radiofrequency consumable backlogs and pain programmes covers the supply side of the same exposure, and the guidance that applies to servicing and parts decisions is covered by AAMI’s medical device servicing material, with independent guidance from organisations such as ECRI on how equipment risk is assessed in a device programme.

Where a device’s continued use depends on consumables, the obligation to keep equipment available and safe continues throughout the period of use, and the duty framing in national workplace material such as the HSE health services guidance is a reminder that commercial arrangements do not displace it. Device-side expectations that apply to equipment on the market, and to the supply of items used with it, are illustrated by the MHRA guidance on regulating medical devices and summarised across markets by the WHO medical devices programme.